Key Takeaways
- Mileutis, an Israeli biopharmaceutical company, announced a significant investment and expanded collaboration with Yotvata Dairy.
- Yotvata Dairy will invest millions in Mileutis and implement Imilac™ therapy to replace antibiotics in dairy farms.
- The partnership includes a new management system prototype for antibiotic-free dairy farming.
- Clinical trials showed Imilac™ increases milk quality, yield, and reduces greenhouse gas emissions.
- Mileutis plans to bring Imilac™ to the global dairy industry, projecting significant revenue potential.
Mileutis Announces Major Investment and Partnership with Yotvata Dairy
Israeli biopharmaceutical company Mileutis has announced a significant investment and expanded collaboration with Yotvata Dairy. As part of this agreement, Yotvata Dairy Farm will invest millions of New Israeli Shekels in Mileutis, signaling a strong commitment to enhancing sustainability and milk quality. Yotvata Dairy has also committed to replacing antibiotics for treating and preventing infections with Mileutis’ Imilac™ therapy across the Israeli dairy farms that supply it with milk.
Advancing Sustainable Dairy Farming
The collaboration will also see the implementation of a cutting-edge management system for dairy farms, serving as a prototype for managing commercial dairy operations without routine antibiotic use during the dry period and lactation. This initiative aligns with Mileutis’ mission to redefine the dairy industry by moving away from traditional reliance on antibiotics towards more sustainable and environmentally friendly practices.
David Javier Iscovich, CEO and co-founder of Mileutis, highlighted the importance of this development: “We are thrilled to take the next step in improving the dairy industry for all stakeholders – consumers, dairy farmers, and, of course, the cows. The agreement with Yotvata is another milestone towards our vision of leading the dairy industry into a sustainable future, which is facing significant challenges.”
Successful Clinical Trials and Impact on Milk Quality
The partnership follows a successful clinical trial conducted in collaboration with Yotvata. Mileutis’ flagship product, Imilac™, demonstrated its effectiveness in replacing antibiotics in dairy cows when administered at dry-off. The trial, involving over 500 cows across seven large Israeli dairy farms, showed that Imilac™ could not only replace antibiotics but also increase milk quality and yield.
Ram Srugo, CEO of Yotvata Dairy from the Strauss Group, commented on the trial’s outcomes: “The launch of the new Yotvata Dairy Farm with Mileutis will help us improve the welfare of the cows and implement a crucial part of the sustainability goals in dairy farming. For our dairy farmers, this will be a significant breakthrough in the quality and yield of milk, with positive implications for the health of the herd. It will also have a positive impact on protecting the environment and will help reduce greenhouse gas emissions.”
Benefits of Imilac™ and Milac™ Therapies
Mileutis’ Imilac™ and Milac™ therapies represent a shift towards more sustainable practices in dairy farming. These products offer several benefits:
- Reduction in Greenhouse Gas Emissions: By increasing milk yield per cow, these therapies reduce the carbon footprint per kilogram of milk. Many large dairy processing companies aim to become carbon neutral by 2050.
- Minimized Antibiotic Use: These therapies are expected to reduce antibiotic usage in dairy farms by up to 90%, significant considering animals currently account for about 70% of global antibiotic usage.
- Improved Animal Welfare: Clinical trials have shown that Imilac™ increases the comfort and welfare of dairy cows.
- Enhanced Farmer Income and Productivity: By boosting milk productivity, these therapies enhance farmers’ incomes and profitability.
- Residue-Free Technology: Imilac™ and Milac™ improve milk quality using a residue-free technology, ensuring healthier dairy products for consumers.
Global Market Potential
Mileutis plans to introduce Imilac™ to the global dairy industry, with an estimated potential annual revenue exceeding $1 billion. The company’s residue-free peptide is the first in a series of patented products aimed at addressing milk quality and sustainability concerns in the global dairy industry.
Mileutis’ technology has received positive feedback from regulatory bodies. The European Medicines Agency (EMA) issued a positive opinion on the safety of Mileutis’ leading product and platform, acknowledging that its casein hydrolysate product does not require a Maximum Residue Limit (MRL) evaluation.
David Javier Iscovich emphasized the broader impact of their technology: “Our technology enhances the quality profile of milk, making it healthier for consumers while also being more environmentally friendly and improving animal welfare. Dairy companies around the world are starting to recognize that Mileutis’ innovative solutions are poised to propel the industry forward towards a more sustainable future, benefiting consumers, dairy farmers, and animals alike.”
Photo by Angelina Litvin on Unsplash
